SEC Form 4 · accession 0001193125-26-335082
Obsidian Therapeutics, Inc. · OBX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Madan Jagasia
Officer — Chief Executive Officer · Director
Period of report
Aug 3, 2026
Accepted (ET)
Aug 5, 2026 · 4:08 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002130606
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $12.00 | Aug 3, 2026 | A | 37,653 | A | — | Aug 2, 2036 | Common Stock | 37,653 | 37,653 | D |
Explanation of responses
- F1The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.